Single domain antibody targeting HBV full-length envelope protein and its use
By targeting the full-length envelope protein of HBV with single-domain antibodies and their derivatives, the treatment challenges of liver cancer caused by HBV infection have been solved, achieving highly efficient and specific treatment for HBV-related liver cancer, activating HBV-specific T cells, and improving the survival rate of patients with advanced HCC.
Patent Information
- Application Number
- CN202410379305.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-03-29
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2044-03-29
AI Technical Summary
Existing treatments for hepatocellular carcinoma (HCC) are ineffective in advanced stages, especially for HCC caused by hepatitis B virus (HBV) infection. Current treatment options are limited, and HBV-specific T cells are dysfunctional in HCC patients, leading to delayed immune attack.
Develop specific single-domain antibodies and their derivatives targeting the full-length HBV envelope protein, such as humanized single-domain antibodies, bispecific antibodies, chimeric antigen receptors, and ADCs, for the preparation of drugs to treat tumors. By binding to the full-length HBV envelope protein with high affinity, they can activate HBV-specific T cells and achieve targeted therapy for liver cancer.
It has achieved highly efficient and specific treatment for HBV-related liver cancer, activated HBV-specific T cells, and improved the survival rate and treatment effect of patients with advanced HCC.
Smart Images

Figure BDA0004767868250000021 
Figure BDA0004767868250000031 
Figure BDA0004767868250000151
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biotechnology, and more specifically to a single domain antibody targeting the full-length envelope protein of HBV and its use. Background Art
[0002] Hepatocellular carcinoma (HCC) is one of the most common highly malignant cancers in the world, characterized by rapid progression, poor prognosis, and a 5-year survival rate of less than 5%. Currently, effective treatment options for liver cancer patients are limited to the early stages of the disease with low tumor burden. The clinical treatment of HCC is still mainly surgical resection, chemotherapy, and radiotherapy, but the degree of benefit to patients is not high, and most patients eventually die from disease recurrence or metastasis. Some tyrosine kinase inhibitors such as sorafenib, lenvatinib, and cabozantinib have been approved for HCC, but clinical observations show that the overall survival of patients with advanced HCC is poor. Immune checkpoint blockade (ICB) therapy is a new treatment for liver cancer, and its efficacy alone or in combination with kinase inhibitors has different remission rates and survival benefits in HCC patients (Kudo M et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 391, 1163-1173 (2018)). Despite the progress made in existing treatments, effective and durable systemic treatment options for HCC are still limited.
[0003] China is a high-incidence area of HCC, of which about 75-80% of HCC patients are induced by hepatitis B virus (HBV) infection. The virus-specific T cells in these HCC patients are often deleted or dysfunctional, resulting in their immune attack to eliminate cancer cells being usually delayed (Hao XS, et al. Twenty-year trends of primary liver cancer incidence rates in an urban Chinese population. Eur J Cancer Prev 12.273-279 (2003)). This problem can be overcome by TCR-T therapy. More than 90% of HBV-HCC have HBV DNA integration and may express complete or truncated HBV antigens, which are processed and presented by MHC molecules on the surface of HBV-infected hepatocytes or HCC cells and can be specifically recognized by T cells. HBV, as an alien invader, is not highly homologous to the endogenous human genome, so it is worth expecting to use HBV-specific T cell receptor-modified T cells (HBV-TCR T cells) to treat HBV-HCC. At present, several patients with advanced HBV-HCC have been reported to be safe and have potential therapeutic effects after receiving HBsAg-specific TCR redirected T cell immunotherapy (Fanping Meng et al., Immunotherapy of HBV-related advanced hepatocellular carcinoma with short-term HBV-specific TCRexpressed T cells: results of dose escalation, phase I trial. Hepatol Int 15(6), 1402-1412(2021)). Therefore, there is an urgent need for effective drugs for the treatment of HBV infection and HBV-induced liver cancer.
[0004] Single-domain antibodies (sdAbs) are a special type of antibody with a smaller molecular weight. Single-domain antibodies consist of only two identical heavy chains. Compared with the molecular weight of 150-160kDa of traditional double-chain antibodies, the molecular weight of single-domain antibodies is about 110KD. Single-domain antibodies generally have high specificity, high affinity, low immunogenicity, and good permeability. The antigen-binding region of a single-domain antibody consists of only one chain, and the variable region (VHH) of a single-domain antibody is only 12-15kDa. Therefore, it is very simple to structurally modify single-domain antibodies, and there will be no problem of mismatching of the light and heavy chains of traditional double-linked antibodies, nor will there be a decrease in affinity caused by modification of the single chain of the antigen-binding region. Single-domain antibodies can recognize cell membrane proteins, and can also recognize polypeptides derived from intracellular proteins presented to the cell surface by major histocompatibility antigens. Summary of the invention
[0005] The purpose of the present invention is to provide a specific single domain antibody targeting the full-length envelope protein of HBV and corresponding specific humanized single domain antibodies, bispecific antibodies, chimeric antigen receptors, chimeric antigen receptor-T cells and ADCs targeting the full-length envelope protein of HBV.
[0006] The present invention also aims to provide the use of the single domain antibody, humanized single domain antibody, bispecific antibody, chimeric antigen receptor, chimeric antigen receptor-T cell and ADC in treating tumors or preparing drugs for treating tumors.
[0007] In a first aspect, the present invention provides a VHH chain of a single-domain antibody targeting a full-length HBV envelope protein, wherein the VHH chain comprises CDR1, CDR2 and CDR3 as shown in the following table:
[0008]
[0009] In a preferred embodiment, the amino acid sequence of the HBV full-length envelope protein is as shown in GLSPTVWLSV (SEQ ID NO: 36).
[0010] In a preferred embodiment, any one of the above-mentioned amino acid sequences also includes a derivative sequence that is optionally added, deleted, modified and / or substituted with at least one (such as 1-3, preferably 1-2, and more preferably 1) amino acid and can retain high affinity binding to the full-length envelope protein of HBV.
[0011] In a preferred embodiment, the VHH chain further comprises framework regions FR1, FR2, FR3 and FR4.
[0012] In a preferred embodiment, the amino acid sequence of the VHH chain of the single-domain antibody targeting the full-length envelope protein of HBV is as shown in SEQ ID NO: 1 or 5.
[0013] In a second aspect, the present invention provides a heavy chain variable region of an antibody targeting the full-length envelope protein of HBV, wherein the heavy chain variable region comprises CDR1, CDR2 and CDR3 as shown in the following table:
[0014]
[0015] In a preferred embodiment, the amino acid sequence of the heavy chain variable region of the antibody targeting the full-length HBV envelope protein is as shown in SEQ ID NO: 1 or 5.
[0016] In a third aspect, the present invention provides a single domain antibody targeting the full-length envelope protein of HBV, which has the VHH chain described in the first aspect.
[0017] In a fourth aspect, the present invention provides a humanized VHH chain of a single-domain antibody targeting the full-length envelope protein of HBV, wherein the framework regions FR1, FR2, FR3 and FR4 are humanized based on the VHH chain described in the first aspect.
[0018] In a preferred embodiment, the amino acid sequence of the humanized VHH chain is shown in any one of SEQ ID NOs: 24-35; preferably, in any one of SEQ ID NOs: 24-30, 32, 33 and 35.
[0019] In the fifth aspect, the present invention provides an antibody targeting the full-length envelope protein of HBV, wherein the antibody comprises one or more VHH chains of the single-domain antibody targeting the full-length envelope protein of HBV described in the first aspect or the humanized VHH chain of the single-domain antibody targeting the full-length envelope protein of HBV described in the fourth aspect.
[0020] In a preferred embodiment, the antibody targeting the full-length HBV envelope protein includes a monomer, a bivalent antibody, and / or a multivalent antibody.
[0021] In the sixth aspect, the present invention provides a bispecific antibody, comprising a first antibody and a second antibody, wherein the first antibody comprises the VHH chain of the single-domain antibody targeting the full-length envelope protein of HBV described in the first aspect, or the heavy chain variable region of the antibody targeting the full-length envelope protein of HBV described in the second aspect, or the single-domain antibody targeting the full-length envelope protein of HBV described in the third aspect, the VHH chain of the humanized single-domain antibody targeting the full-length envelope protein of HBV described in the fourth aspect, or the antibody targeting the full-length envelope protein of HBV described in the fifth aspect.
[0022] In a preferred embodiment, the second antibody may bind to the same or a different antigen as the first antibody, or bind to a different epitope on the same antigen as the first antibody.
[0023] In a preferred embodiment, the second antibody is a single domain antibody, a single chain antibody or a double chain antibody.
[0024] In a preferred embodiment, the bispecific antibody comprises 2-4 single-domain antibodies targeting the full-length envelope protein of HBV; preferably, it comprises 2 single-domain antibodies targeting the full-length envelope protein of HBV; more preferably, the 2 single-domain antibodies targeting the full-length envelope protein of HBV form a single-domain antibody dimer targeting the full-length envelope protein of HBV.
[0025] In the seventh aspect, the present invention provides a fusion protein, comprising the VHH chain of the single domain antibody targeting HBV full-length envelope protein as described in the first aspect, the heavy chain variable region of the antibody targeting HBV full-length envelope protein as described in the second aspect, the single domain antibody targeting HBV full-length envelope protein as described in the third aspect, the humanized VHH chain of the single domain antibody targeting HBV full-length envelope protein as described in the fourth aspect, or the antibody targeting HBV full-length envelope protein as described in the fifth aspect, an optional linker sequence and an Fc fragment of an immunoglobulin or a half-life extension domain.
[0026] In a preferred embodiment, the immunoglobulin is IgG1, IgG2, IgG3, IgG4; preferably IgG4.
[0027] In the eighth aspect, the present invention provides a nucleic acid molecule, which encodes the VHH chain of the single-domain antibody targeting the full-length envelope protein of HBV described in the first aspect, the heavy chain variable region of the antibody targeting the full-length envelope protein of HBV described in the second aspect, the single-domain antibody targeting the full-length envelope protein of HBV described in the third aspect, the humanized VHH chain of the single-domain antibody targeting the full-length envelope protein of HBV described in the fourth aspect, the antibody targeting the full-length envelope protein of HBV described in the fifth aspect, the bispecific antibody described in the sixth aspect, or the fusion protein described in the seventh aspect.
[0028] In a ninth aspect, the present invention provides an expression vector comprising the nucleic acid molecule described in the eighth aspect.
[0029] In a tenth aspect, the present invention provides a host cell, wherein the host cell comprises the expression vector described in the ninth aspect, or the nucleic acid molecule described in the eighth aspect is integrated into its genome.
[0030] In an eleventh aspect, the present invention provides a method for preparing the VHH chain of the single-domain antibody targeting the full-length envelope protein of HBV described in the first aspect, the heavy chain variable region of the antibody targeting the full-length envelope protein of HBV described in the second aspect, the single-domain antibody targeting the full-length envelope protein of HBV described in the third aspect, the humanized VHH chain of the single-domain antibody targeting the full-length envelope protein of HBV described in the fourth aspect, the antibody targeting the full-length envelope protein of HBV described in the fifth aspect, the bispecific antibody described in the sixth aspect, or the fusion protein described in the seventh aspect, the method comprising the following steps:
[0031] 1) Cultivating the host cell as described in the tenth aspect under suitable conditions to obtain a culture containing the VHH chain of the single domain antibody targeting the full-length envelope protein of HBV, the heavy chain variable region of the antibody targeting the full-length envelope protein of HBV, the single domain antibody targeting the full-length envelope protein of HBV, the humanized VHH chain of the single domain antibody targeting the full-length envelope protein of HBV, the antibody targeting the full-length envelope protein of HBV, the bispecific antibody or the fusion protein; and
[0032] 2) Optionally, the VHH chain of the single domain antibody targeting the full-length envelope protein of HBV, the heavy chain variable region of the antibody targeting the full-length envelope protein of HBV, the single domain antibody targeting the full-length envelope protein of HBV, the humanized VHH chain of the single domain antibody targeting the full-length envelope protein of HBV, the single domain antibody targeting the full-length envelope protein of HBV, the bispecific antibody or the fusion protein is isolated or recovered from the culture.
[0033] In a twelfth aspect, the present invention provides an immunoconjugate, the immunoconjugate comprising:
[0034] 1) the VHH chain of the single-domain antibody targeting the full-length envelope protein of HBV as described in the first aspect, the heavy chain variable region of the antibody targeting the full-length envelope protein of HBV as described in the second aspect, the single-domain antibody targeting the full-length envelope protein of HBV as described in the third aspect, the humanized VHH chain of the single-domain antibody targeting the full-length envelope protein of HBV as described in the fourth aspect, the antibody targeting the full-length envelope protein of HBV as described in the fifth aspect, the bispecific antibody as described in the sixth aspect, or the fusion protein as described in the seventh aspect; and
[0035] 2) A conjugated moiety selected from the group consisting of a detectable label, a drug, a toxin, a cytokine, a radionuclide, or an enzyme.
[0036] In a preferred embodiment, the conjugated moiety is a drug or a toxin.
[0037] In a preferred embodiment, the immunoconjugate is an antibody-drug conjugate (ADC) or a radionuclide drug conjugate (RDC).
[0038] In a preferred embodiment, the conjugated moiety is a detectable label.
[0039] In a preferred embodiment, the conjugate is selected from: fluorescent or luminescent markers, radioactive markers, MRI (magnetic resonance imaging) or CT (computer tomography) contrast agents, or enzymes capable of producing detectable products, radionuclides, biotoxins, cytokines (such as IL-2, etc.), antibodies, antibody Fc fragments, antibody scFv fragments, gold nanoparticles / nanorods, viral particles, liposomes, nanomagnetic particles, prodrug activating enzymes (for example, DT-diaphorase (DTD) or biphenyl hydrolase-like protein (BPHL)), chemotherapeutic agents (for example, cisplatin) or any form of nanoparticles, etc.
[0040] In a preferred embodiment, the immunoconjugate contains: a multivalent (e.g., bivalent) VHH chain of a single-domain antibody targeting the full-length envelope protein of HBV as described in the first aspect, a heavy chain variable region of an antibody targeting the full-length envelope protein of HBV as described in the second aspect, a single-domain antibody targeting the full-length envelope protein of HBV as described in the third aspect, a humanized VHH chain of a single-domain antibody targeting the full-length envelope protein of HBV as described in the fourth aspect, an antibody targeting the full-length envelope protein of HBV as described in the fifth aspect, a bispecific antibody as described in the sixth aspect, or a fusion protein as described in the seventh aspect.
[0041] In a preferred embodiment, the multivalency refers to the presence of multiple repeating parts in the amino acid sequence of the immunoconjugate.
[0042] In a thirteenth aspect, the present invention provides a chimeric antigen receptor, wherein the chimeric antigen receptor comprises the single domain antibody described in the third aspect or is prepared by the single domain antibody described in the third aspect.
[0043] In a preferred embodiment, the amino acid sequence of the chimeric antigen receptor is as shown in SEQ ID NO: 22 or 23.
[0044] In a fourteenth aspect, the present invention provides an immune effector cell, wherein the immune effector cell expresses the chimeric antigen receptor described in the thirteenth aspect on its surface.
[0045] In a preferred embodiment, the immune effector cells include but are not limited to T cells or NK cells; preferably T cells.
[0046] In the fifteenth aspect, the present invention provides a pharmaceutical composition, comprising a therapeutically or diagnostically effective amount of the VHH chain of the single domain antibody targeting the full-length envelope protein of HBV as described in the first aspect, the heavy chain variable region of the antibody targeting the full-length envelope protein of HBV as described in the second aspect, the single domain antibody targeting the full-length envelope protein of HBV as described in the third aspect, the humanized VHH chain of the single domain antibody targeting the full-length envelope protein of HBV as described in the fourth aspect, the antibody targeting the full-length envelope protein of HBV as described in the fifth aspect, the bispecific antibody as described in the sixth aspect, the fusion protein as described in the seventh aspect, the immunoconjugate as described in the twelfth aspect or the immune effector cell as described in the fourteenth aspect, and optional pharmaceutically acceptable excipients.
[0047] In a preferred embodiment, the pharmaceutical composition is used to treat HBV full-length envelope protein-related diseases; preferably, the HBV full-length envelope protein-related diseases are tumors or hepatitis B virus infection.
[0048] In a preferred embodiment, said tumor is liver cancer; preferably hepatocellular carcinoma.
[0049] In the sixteenth aspect, the present invention provides the use of the VHH chain of the single-domain antibody targeting the full-length envelope protein of HBV described in the first aspect, the heavy chain variable region of the antibody targeting the full-length envelope protein of HBV described in the second aspect, the single-domain antibody targeting the full-length envelope protein of HBV described in the third aspect, the humanized VHH chain of the single-domain antibody targeting the full-length envelope protein of HBV described in the fourth aspect, the antibody targeting the full-length envelope protein of HBV described in the fifth aspect, the bispecific antibody described in the sixth aspect, the fusion protein described in the seventh aspect, the immunoconjugate described in the twelfth aspect, the immune effector cell described in the fourteenth aspect, or the pharmaceutical composition described in the fifteenth aspect, for preparing the following reagents:
[0050] 1) Reagents for detecting the full-length HBV envelope protein;
[0051] 2) Reagents that block the binding of HBV full-length envelope protein to PD-L1;
[0052] 3) Drugs for treating diseases related to HBV full-length envelope protein.
[0053] In a preferred embodiment, the HBV full-length envelope protein-related disease is a tumor or hepatitis B virus infection.
[0054] In a preferred embodiment, said tumor is liver cancer; preferably hepatocellular carcinoma.
[0055] In a seventeenth aspect, the present invention provides a kit, comprising:
[0056] 1) the VHH chain of the single-domain antibody targeting the full-length envelope protein of HBV described in the first aspect, the heavy chain variable region of the antibody targeting the full-length envelope protein of HBV described in the second aspect, the single-domain antibody targeting the full-length envelope protein of HBV described in the third aspect, the humanized VHH chain of the single-domain antibody targeting the full-length envelope protein of HBV described in the fourth aspect, the antibody targeting the full-length envelope protein of HBV described in the fifth aspect, the bispecific antibody described in the sixth aspect, the fusion protein described in the seventh aspect, the immunoconjugate described in the twelfth aspect, the immune effector cell described in the fourteenth aspect, or the pharmaceutical composition described in the fifteenth aspect;
[0057] 2) container; and
[0058] 3) Optional instruction manual.
[0059] In an eighteenth aspect, the present invention provides a method for detecting a full-length HBV envelope protein in a sample, the method comprising the steps of:
[0060] 1) contacting the sample to be tested with the VHH chain of the single domain antibody targeting the full-length envelope protein of HBV described in the first aspect, the heavy chain variable region of the antibody targeting the full-length envelope protein of HBV described in the second aspect, the single domain antibody targeting the full-length envelope protein of HBV described in the third aspect, the VHH chain of the humanized single domain antibody targeting the full-length envelope protein of HBV described in the fourth aspect, the antibody targeting the full-length envelope protein of HBV described in the fifth aspect, the bispecific antibody described in the sixth aspect, the fusion protein described in the seventh aspect, or the immunoconjugate described in the twelfth aspect;
[0061] 2) Detect whether an antigen-antibody complex is formed. If a complex is formed, it indicates that the full-length HBV envelope protein is present in the sample.
[0062] In the nineteenth aspect, the present invention provides a method for treating a disease, the method comprising administering to a subject in need thereof a therapeutically effective amount of the VHH chain of the single-domain antibody targeting the full-length envelope protein of HBV described in the first aspect, the heavy chain variable region of the antibody targeting the full-length envelope protein of HBV described in the second aspect, the single-domain antibody targeting the full-length envelope protein of HBV described in the third aspect, the humanized VHH chain of the single-domain antibody targeting the full-length envelope protein of HBV described in the fourth aspect, the antibody targeting the full-length envelope protein of HBV described in the fifth aspect, the bispecific antibody described in the sixth aspect, the fusion protein described in the seventh aspect, the immunoconjugate described in the twelfth aspect, or the immune effector cell described in the fourteenth aspect or the pharmaceutical composition described in the fifteenth aspect.
[0063] In a preferred embodiment, the subject comprises a mammal; preferably a human.
[0064] In a preferred embodiment, the disease is a disease associated with the full-length HBV envelope protein; preferably, the disease associated with the full-length HBV envelope protein is a tumor or hepatitis B virus infection.
[0065] In a preferred embodiment, said tumor is liver cancer; preferably hepatocellular carcinoma.
[0066] It should be understood that within the scope of the present invention, the above-mentioned technical features of the present invention and the technical features specifically described below (such as embodiments) can be combined with each other to form a new or preferred technical solution. Due to space limitations, they will not be described one by one here. BRIEF DESCRIPTION OF THE DRAWINGS
[0067] Figure 1 Demonstrating that the candidate single domain antibodies of the present invention can bind to antigenic proteins with high affinity;
[0068] Figure 2 It is shown that the candidate single domain antibodies of the present invention can bind to the target protein with high affinity at the cellular level;
[0069] Figure 3 It is shown that the candidate single domain antibody of the present invention can specifically bind to the HBV polypeptide-HLA-A02 complex antigen at the cellular level;
[0070] Figure 4 The expression of the CAR molecule of the present invention on T cells is shown;
[0071] Figure 5 The killing effect of the CAR-T cells of the present invention on target cells is shown;
[0072] Figure 6 It shows that the CAR-T cells of the present invention can effectively recognize T2 loaded with target polypeptides, activate and transmit immune signals, and secrete IFN-γ and IL-2 cytokines, among which the biological activity of HBV-CAR-T-02 molecule is relatively better;
[0073] Figure 7 It is shown that the humanized single domain antibody of the present invention can bind to protein antigens with higher affinity. DETAILED DESCRIPTION
[0074] The MHC class I molecule HLA-A02 can specifically present the GLSPTVWLSV peptide segment of the full-length HBV envelope protein, so the HBV antigen can be presented to the cell surface and recognized by antibodies. The present invention uses the HLA-A02 complex of the polypeptide bound to the HBV envelope protein as an antigen to screen specific single-domain antibody molecules. These candidate molecules can be used to develop bispecific antibodies, CAR-T or ADC (Antibody drug conjugate) and other biological drugs. The polypeptide sequence used in the present invention is shared by the HBV envelope protein.
[0075] Specifically, after extensive and in-depth research, the inventors unexpectedly discovered a class of single-domain antibodies targeting the full-length envelope protein of HBV. The single-domain antibodies of the present invention can bind to the full-length envelope protein of HBV with high affinity and have good specificity. The present invention also provides bispecific antibodies, chimeric antigen receptors, chimeric antigen receptor-T cells, and ADCs prepared using the single-domain antibodies. The present invention was completed on this basis.
[0076] Definition of terms
[0077] The terms used herein have the same or similar meanings as those conventionally understood by those skilled in the art. For the sake of clarity, some of the terms are defined as follows.
[0078] Single domain antibodies
[0079] In this article, "single domain antibody", "single domain antibody", "nanoantibody" and the like have the same or similar meanings, and all refer to a type of antibody molecule that lacks the antibody light chain and only has the heavy chain variable region. A single domain antibody is the smallest antigen binding unit, that is, the smallest antigen binding fragment with complete function. Usually, an antibody that naturally lacks the light chain and heavy chain constant region 1 (CH1) is obtained first, and then the variable region of the antibody heavy chain is cloned, thereby constructing a single domain antibody (VHH) consisting of only one heavy chain variable region.
[0080] The single-domain antibody VHH chain targeting the full-length HBV envelope protein of the present invention also includes framework regions FR1, FR2, FR3 and FR4.
[0081] Based on the single-domain antibody VHH chain targeting the full-length envelope protein of HBV of the present invention, the inventors also humanized the VHH chain to obtain a humanized single-domain antibody VHH chain targeting the full-length envelope protein of HBV.
[0082] On the basis of the single-domain antibody VHH chain or humanized VHH chain targeting the full-length envelope protein of HBV of the present invention, the present invention also provides an antibody targeting the full-length envelope protein of HBV, which includes one or more VHH chains of the single-domain antibody targeting the full-length envelope protein of HBV or the humanized VHH chain of the single-domain antibody targeting the full-length envelope protein of HBV. The present invention also provides a bispecific antibody, the bispecific antibody includes a first antibody and a second antibody, the first antibody may be the VHH chain of the single-domain antibody targeting the full-length envelope protein of HBV of the present invention, or the humanized VHH chain. Those skilled in the art can select the second antibody in the bispecific antibody according to actual needs. For example, the second antibody may bind to the same or different antigen as the first antibody; if the second antibody binds to the same antigen as the first antibody, it is preferably bound to a different epitope. In a specific embodiment, the second antibody may be a single-domain antibody, a single-chain antibody, or a double-chain antibody.
[0083] Those skilled in the art can also prepare a fusion protein from the single-domain antibody VHH chain or humanized VHH chain targeting the full-length envelope protein of HBV of the present invention, for example, a fusion protein further comprising an Fc fragment or a half-life extension domain of an immunoglobulin. The fusion protein thus obtained not only has the biological activity of the single-domain antibody VHH chain itself, but also has other properties conferred by the Fc fragment of the immunoglobulin, such as extended plasma half-life, reduced immunogenicity, improved stability, and the like. In a specific embodiment, the fusion protein comprises a VHH chain or a humanized VHH chain of a single-domain antibody targeting the full-length envelope protein of HBV of the present invention, an optional linker sequence, and an Fc fragment or a half-life extension domain of an immunoglobulin. In a specific embodiment, the immunoglobulin is IgG1, IgG2, IgG3, IgG4; preferably IgG4.
[0084] The present invention includes not only complete antibodies, but also fragments, derivatives and analogs of the antibodies. As used herein, the terms "fragment", "derivative" and "analog" refer to polypeptides that substantially retain the same biological function or activity as the antibodies of the present invention. The polypeptide fragments, derivatives or analogs of the present invention may be (i) polypeptides in which one or more conservative or non-conservative amino acid residues (preferably conservative amino acid residues) are substituted, and such substituted amino acid residues may or may not be encoded by the genetic code, or (ii) polypeptides having a substitution group in one or more amino acid residues, or (iii) polypeptides formed by fusion of a mature polypeptide with another compound (such as a compound that prolongs the half-life of the polypeptide, such as polyethylene glycol), or (iv) polypeptides formed by fusion of an additional amino acid sequence to this polypeptide sequence (such as a leader sequence or secretory sequence or a sequence or proprotein sequence used to purify the polypeptide, or a fusion protein formed with a 6His tag). According to the teachings of this article, these fragments, derivatives and analogs belong to the scope known to those skilled in the art.
[0085] The antibody of the present invention refers to a polypeptide having HBV full-length envelope protein binding activity and including the above-mentioned CDR region. The term also includes variant forms of polypeptides having the same function as the antibody of the present invention and including the above-mentioned CDR region. These variant forms include (but are not limited to): one or more (usually 1-50, preferably 1-30, more preferably 1-20, and optimally 1-10) amino acid deletions, insertions and / or substitutions, and addition of one or several (usually within 20, preferably within 10, and more preferably within 5) amino acids at the C-terminus and / or N-terminus. For example, in the art, when amino acids with similar or similar properties are substituted, the function of the protein is usually not changed. For another example, adding one or several amino acids at the C-terminus and / or N-terminus usually does not change the function of the protein. The term also includes active fragments and active derivatives of the antibodies of the present invention. Variant forms of the polypeptide include: homologous sequences, conservative variants, allelic variants, natural mutants, induced mutants, proteins encoded by DNA that can hybridize with the encoding DNA of the antibody of the present invention under high or low stringency conditions, and polypeptides or proteins obtained using antiserum against the antibody of the present invention.
[0086] In addition to almost full-length polypeptides, the present invention also includes fragments of the single domain antibodies of the present invention. Typically, the fragment has at least about 50 consecutive amino acids of the antibody of the present invention, preferably at least about 50 consecutive amino acids, more preferably at least about 80 consecutive amino acids, and most preferably at least about 100 consecutive amino acids.
[0087] In the present invention, "conservative variants of the antibodies of the present invention" refer to polypeptides formed by replacing at most 10, preferably at most 8, more preferably at most 5, and most preferably at most 3 amino acids with amino acids of similar or similar properties compared to the amino acid sequence of the antibodies of the present invention. These conservative variant polypeptides are preferably generated by amino acid substitution according to the following table.
[0088] Initial residue Representative replacement Preferred substitutions Ala(A) Val; Leu; Ile Val Arg(R) Lys; Gln; Asn Lys Asn(N) Gln; His; Lys; Arg Gln Asp(D) Glu Glu Cys(C) Ser Ser Gln(Q) Asn Asn Glu(E) Asp Asp Gly(G) Pro; Ala Ala His(H) Asn; Gln; Lys; Arg Arg Ile(I) Leu; Val; Met; Ala; Phe Leu Leu(L) Ile; Val; Met; Ala; Phe Ile Lys(K) Arg; Gln; Asn Arg Met(M) Leu; Phe; Ile Leu Phe(F) Leu; Val; Ile; Ala; Tyr Leu Pro(P) Ala Ala Ser(S) Thr Thr Thr(T) Ser Ser Trp(W) Tyr; Phe Tyr Tyr(Y) Trp; Phe; Thr; Ser Phe Val(V) Ile; Leu; Met; Phe; Ala Leu
[0089] The present invention also provides a polynucleotide molecule encoding the above-mentioned antibody or its fragment or its fusion protein. The polynucleotide of the present invention can be in the form of DNA or RNA. The DNA form includes cDNA, genomic DNA or artificially synthesized DNA. DNA can be single-stranded or double-stranded. DNA can be a coding strand or a non-coding strand. The polynucleotide encoding the mature polypeptide of the present invention includes: a coding sequence that only encodes a mature polypeptide; a coding sequence of a mature polypeptide and various additional coding sequences; a coding sequence of a mature polypeptide (and optional additional coding sequences) and a non-coding sequence.
[0090] The term "polynucleotide encoding a polypeptide" may include a polynucleotide encoding the polypeptide, or may include additional coding and / or non-coding sequences. The present invention also relates to polynucleotides that hybridize with the above-mentioned sequences and have at least 50%, preferably at least 70%, and more preferably at least 80% identity between the two sequences. The present invention particularly relates to polynucleotides that can hybridize with the polynucleotides of the present invention under stringent conditions. In the present invention, "stringent conditions" refer to: (1) hybridization and elution at relatively low ionic strength and relatively high temperature, such as 0.2×SSC, 0.1% SDS, 60°C; or (2) addition of denaturing agents during hybridization, such as 50% (v / v) formamide, 0.1% calf serum / 0.1% Ficoll, 42°C, etc.; or (3) hybridization occurs only when the identity between the two sequences is at least 90%, preferably at least 95%. In addition, the polypeptide encoded by the hybridizable polynucleotide has the same biological function and activity as the mature polypeptide.
[0091] The full-length nucleotide sequence of the antibody of the present invention or its fragment can usually be obtained by PCR amplification, recombination or artificial synthesis. A feasible method is to synthesize the relevant sequence by artificial synthesis, especially when the fragment length is short. Usually, a fragment with a very long sequence can be obtained by first synthesizing multiple small fragments and then connecting them. In addition, the coding sequence of the heavy chain and the expression tag (such as 6His) can be fused together to form a fusion protein. Once the relevant sequence is obtained, the relevant sequence can be obtained in large quantities by recombination. This is usually done by cloning it into a vector, then transferring it into cells, and then isolating the relevant sequence from the proliferated host cells by conventional methods. The biological molecules (nucleic acids, proteins, etc.) involved in the present invention include biological molecules in an isolated form.
[0092] At present, the DNA sequence encoding the protein of the present invention (or its fragment, or its derivative) can be obtained completely by chemical synthesis. The DNA sequence can then be introduced into various existing DNA molecules (or vectors) and cells known in the art. In addition, mutations can also be introduced into the protein sequence of the present invention by chemical synthesis.
[0093] The present invention also relates to vectors comprising the above-mentioned appropriate DNA sequence and appropriate promoter or control sequence. These vectors can be used to transform appropriate host cells to enable them to express proteins. The host cell can be a prokaryotic cell, such as a bacterial cell; or a lower eukaryotic cell, such as a yeast cell; or a higher eukaryotic cell, such as a mammalian cell. Representative examples include: Escherichia coli, Streptomyces; bacterial cells of Salmonella typhimurium; fungal cells such as yeast; insect cells of Drosophila S2 or Sf9; animal cells of CHO, COS7, 293 cells, etc.
[0094] Transformation of host cells with recombinant DNA can be performed using conventional techniques well known to those skilled in the art. When the host is a prokaryotic organism such as Escherichia coli, competent cells that can absorb DNA can be harvested after the exponential growth phase and treated with the CaCl2 method, the steps used are well known in the art. Another method is to use MgCl2. If necessary, transformation can also be performed using electroporation. When the host is a eukaryotic organism, the following DNA transfection methods can be selected: calcium phosphate coprecipitation method, conventional mechanical methods such as microinjection, electroporation, liposome packaging, etc.
[0095] The obtained transformant can be cultured by conventional methods to express the polypeptide encoded by the gene of the present invention. Depending on the host cell used, the culture medium used in the culture can be selected from various conventional culture media. Culture is carried out under conditions suitable for the growth of the host cells. After the host cells grow to an appropriate cell density, the selected promoter is induced by a suitable method (such as temperature conversion or chemical induction), and the cells are cultured for a period of time.
[0096] The recombinant polypeptide in the above method can be expressed in the cell, on the cell membrane, or secreted outside the cell. If necessary, the recombinant protein can be separated and purified by various separation methods using its physical, chemical and other properties. These methods are well known to those skilled in the art. Examples of these methods include but are not limited to: conventional renaturation treatment, treatment with a protein precipitant (salting out method), centrifugation, osmotic sterilization, ultra-treatment, ultracentrifugation, molecular sieve chromatography (gel filtration), adsorption chromatography, ion exchange chromatography, high performance liquid chromatography (HPLC) and other various liquid chromatography techniques and combinations of these methods.
[0097] The antibodies of the present invention can be used alone or in combination or conjugated with a detectable marker (for diagnostic purposes), a therapeutic agent, a PK (protein kinase) modification moiety, or any combination of these substances. Detectable markers for diagnostic purposes include, but are not limited to, fluorescent or luminescent markers, radioactive markers, MRI (magnetic resonance imaging) or CT (computer tomography) contrast agents, or enzymes capable of producing a detectable product.
[0098] Therapeutic agents that can be combined or coupled to the antibodies of the present invention include, but are not limited to: 1. radionuclides; 2. biological toxins; 3. cytokines, such as IL-2, etc.; 4. gold nanoparticles / nanorods; 5. viral particles; 6. liposomes; 7. nanomagnetic particles; 8. drug-activated enzymes (e.g., DT-diaphorase (DTD) or biphenyl hydrolase-like protein (BPHL)); 9. therapeutic agents (e.g., cisplatin) or any form of nanoparticles, etc.
[0099] Bispecific Antibodies
[0100] Bispecific antibodies are recombinant antibodies that have been engineered through protein engineering. Bispecific antibodies can simultaneously target two different antibody binding epitopes, which can be from different antigens or from the same antigen. Many current studies have shown that bispecific antibodies have great therapeutic potential in the treatment of diseases such as tumors, autoimmune diseases and viral infections. Compared with monoclonal antibodies, the main advantage of bispecific antibodies is that they can mediate the spatial effect of two recognition epitopes and the synergistic effect of dual targeting, producing biological effects that cannot be achieved by the combined use of two antibodies. A relatively special bispecific antibody is called a T cell engager, which can simultaneously bind to targets and T cells on the surface of tumor cells, activate endogenous T cells, and cause tumor cell lysis, thereby achieving the purpose of treating tumors. T cell engagers have been shown to be used to treat tumors. Bispecific T cell engagers targeting CD20 and CD19 have been approved by the FDA for marketing (Nat Rev Clin Oncol. 2020 Jul; 17 (7): 418-434.). Because of their complexity, which is different from monoclonal antibodies, bispecific antibodies have higher technical barriers and R&D costs.
[0101] Immune cells
[0102] In this article, immune cells and immune effector cells have the same meaning, and are the same as those conventionally understood by those skilled in the art. It refers to cells that participate in or are related to immune responses, including lymphocytes and phagocytes. In a specific embodiment, the immune cell refers to a lymphocyte that can recognize antigens, thereby producing a specific immune response. The lymphocytes are mainly T lymphocytes, B lymphocytes, K lymphocytes and NK lymphocytes. In addition to lymphocytes, the cells involved in immune responses also have plasma cells, granulocytes, mast cells, antigen presenting cells and cells of the mononuclear phagocyte system (e.g., macrophages).
[0103] Chimeric Antigen Receptor T Cells
[0104] Chimeric antigen receptor T cell therapy is a very promising cellular immunotherapy. CAR-T cells express CAR (Chimeric Antigen Receptor) molecules, and the structure of CAR is divided into: antigen binding region, hinge region, transmembrane domain, and intracellular signal transduction domain. Current CAR-T cells usually use scFv (Single Chain Fragment Variables) segments derived from single-chain modification of the antigen binding region of monoclonal antibodies as antigen binding regions. However, when scFv structural modification is performed, problems such as reduced affinity and changed specificity are prone to occur. At the same time, scFv has a relatively large molecular weight and is easy to form multimers, which affects the function of CAR (Nat Rev Cancer. 2021Mar; 21(3): 145-161.). Therefore, CAR containing an antigen binding region with a novel structure. Using single-domain antibodies to construct a CAR structure, the variable region of the single-domain antibody can be directly connected to the CAR structure, which is simple and convenient to design.
[0105] Immunoconjugates
[0106] ADC is an antibody carrying cytotoxic drugs, which can deliver cytotoxic drugs to tumor cells to achieve specific killing of tumor cells. ADC drugs targeting targets such as HER2, CD30 and Trop2 have shown good clinical efficacy and safety in clinical studies (Nat Rev Clin Oncol. 2021Jun; 18(6): 327-344.). In recent years, a number of ADC drugs have been approved by the FDA for marketing. However, the targets of ADC drugs are currently cell membrane proteins, and ADC drugs targeting intracellular proteins are one of the hot directions for future development.
[0107] ADC drugs can specifically target target cells and deliver cytotoxic molecules into target cells, thereby producing a specific killing effect. Cell killing induced by cytotoxic molecules can break and improve the tumor suppressive microenvironment, and has the potential to improve the efficacy of other therapies such as immunotherapy. The single-domain antibody of the present invention can be internalized into cells, so there is hope for the development of ADC drugs based on the single-domain antibody of the present invention in the future.
[0108] The present invention also provides an immunoconjugate, which contains the VHH chain of the single-domain antibody targeting the full-length envelope protein of HBV of the present invention, the humanized VHH chain, etc. and a coupling part. In a specific embodiment, the coupling part can be a detectable marker, a drug, a toxin, a cytokine, a radionuclide or an enzyme, etc., so as to achieve the purpose of diagnosis, detection or treatment, etc.
[0109] In a preferred embodiment, the immunoconjugate is an antibody-drug conjugate (ADC) or a radionuclide drug conjugate (RDC).
[0110] Pharmaceutical composition
[0111] The present invention also provides a composition. Preferably, the composition is a pharmaceutical composition, which contains the above-mentioned antibody or its active fragment or its fusion protein, and a pharmaceutically acceptable carrier. Generally, these substances can be formulated in a non-toxic, inert and pharmaceutically acceptable aqueous carrier medium, wherein the pH is generally about 5-8, preferably about 6-8, although the pH value may vary depending on the properties of the formulated substance and the condition to be treated. The formulated pharmaceutical composition can be administered by conventional routes, including (but not limited to): intratumoral, intraperitoneal, intravenous, or local administration.
[0112] The pharmaceutical composition of the present invention can directly target the full-length HBV envelope protein expressed by tumor cells. Therefore, the pharmaceutical composition of the present invention can be used to treat tumors. In a specific embodiment, the tumor is a tumor associated with the full-length HBV envelope protein. In a preferred embodiment, the tumor is melanoma, non-small cell lung cancer, ovarian cancer or breast cancer, etc. In addition, the pharmaceutical composition of the present invention can also be used in combination with other therapeutic agents.
[0113] The pharmaceutical composition of the present invention contains a safe and effective amount (such as 0.001-99wt%, preferably 0.01-90wt%, more preferably 0.1-80wt%) of the above-mentioned single domain antibody (or its conjugate) of the present invention and a pharmaceutically acceptable carrier or excipient. Such carriers include (but are not limited to): saline, buffer, glucose, water, glycerol, ethanol, and combinations thereof. The pharmaceutical preparation should match the mode of administration. The pharmaceutical composition of the present invention can be prepared in the form of an injection, for example, by conventional methods using physiological saline or an aqueous solution containing glucose and other adjuvants. Pharmaceutical compositions such as injections and solutions are preferably manufactured under sterile conditions.
[0114] The dosage of the active ingredient is a therapeutically effective amount, for example, about 10 μg / kg body weight to about 50 mg / kg body weight per day. When using a pharmaceutical composition, a safe and effective amount of the immunoconjugate is administered to a mammal, wherein the safe and effective amount is usually at least about 10 μg / kg body weight, and in most cases does not exceed about 50 mg / kg body weight, preferably the dosage is about 10 μg / kg body weight to about 10 mg / kg body weight. Of course, the specific dosage should also take into account factors such as the route of administration and the patient's health status, which are all within the skill range of skilled physicians.
[0115] Reagent test kit
[0116] The present invention also provides a kit containing the VHH chain of the single-domain antibody targeting the full-length envelope protein of HBV, or the humanized VHH chain, antibody, fusion protein or immunoconjugate of the present invention. In a specific embodiment, the kit further includes a container, instructions for use, a buffer, etc.
[0117] Advantages of the present invention:
[0118] 1. The single-domain antibody targeting the full-length HBV envelope protein of the present invention binds to the full-length HBV envelope protein with high affinity;
[0119] 2. The single-domain antibody targeting the full-length HBV envelope protein of the present invention has good specificity;
[0120] 3. The single-domain antibody targeting the full-length envelope protein of HBV of the present invention can be further used to prepare bispecific antibodies, chimeric antigen receptors, chimeric antigen receptor-T cells, and ADCs, thereby laying a new material foundation for the development of therapeutic or diagnostic drugs targeting the full-length envelope protein of HBV.
[0121] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are intended to illustrate the present invention only and are not intended to limit the scope of the present invention. The experimental methods in the following examples where specific conditions are not specified are usually performed under conventional conditions, such as those described in Sambrook et al., Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989), or under conditions recommended by the manufacturer. Unless otherwise indicated, percentages and parts are weight percentages and weight parts.
[0122] Example 1: Acquisition of single domain antibody sequences
[0123] The present invention selects two adult healthy alpacas (Alpaca) as experimental animals for immunization. The alpacas are immunized using a recombinant protein of pMHC (peptide-Major histocompatibility complex) carrying a target polypeptide as an antigen. The present invention performs 4-5 immunizations in total. During the immunization process, peripheral blood of the alpaca is taken at different time points, and the post-immunization titer is detected using the ELISA method. After the immunization cycle, peripheral blood of the alpaca is taken to obtain PBMCs cells, mRNA is extracted and reversely transcribed, and cDNA of the PBMCs cells is obtained. The cDNA is amplified using specific primers to obtain a PCR product with a single-domain antibody gene fragment. Then, an electroporator is used to introduce the PCR product and the yeast library vector into yeast competent cells to prepare a yeast display library.
[0124] Then, the yeast library is screened using pMHC recombinant proteins carrying the target polypeptide or T2 cells loaded with the target polypeptide. The present invention uses pMHC recombinant proteins carrying the target polypeptide as positive antigens and pMHC recombinant proteins carrying negative polypeptides as negative antigens. After three rounds of positive screening and three rounds of negative screening, single domain antibody clones that specifically bind to positive antigens but not to negative antigens are obtained.
[0125] The single domain antibody clones were subjected to Sanger sequencing to obtain the full-length gene sequence of the single domain antibody. The present invention obtained two different single domain antibody clones, named as LL-HP001 and LL-HP002. The full-length amino acid sequence and CDR region amino acid sequence of the single domain antibody of the present invention are shown in Table 1, and the nucleic acid sequence table is shown in Table 2.
[0126] Table 1. Candidate single domain antibody amino acid sequences
[0127]
[0128]
[0129] Table 2. Candidate single domain antibody nucleic acid sequence list
[0130]
[0131] Example 2: Single domain antibody expression and purification
[0132] The two candidate single-domain antibodies in the present invention are expressed and purified using conventional monoclonal antibody expression and purification methods. First, a single-domain antibody expression vector is constructed using molecular cloning technology. After the vector is successfully constructed, the single-domain antibody is expressed using the transient transfection method of the HEK293 suspension cell line. Basic steps: Clone the single-domain antibody gene into the expression vector pCDNA4 (Invitrogen, Cat V86220). Different single-domain antibodies are expressed using the transient transfection method of HEK293 suspension cells. After the expression is completed, the supernatant is collected and the single-domain antibody of the present invention is purified using a conventional monoclonal antibody purification method.
[0133] After purification, the protein concentration and total protein amount of different antibodies were detected by ultraviolet spectrophotometry, and then the expression amount of each single domain antibody was calculated according to the expression volume. The absorbance value A280 of the sample solution was read at a wavelength of 280nm using NanoDrop 1000, and the protein concentration of the sample was calculated by the formula C (mg / mL) = A280 / ε (ε is 1.482mL / mg·cm-1). At the same time, the purity of different antibodies was evaluated using the conventional gel electrophoresis SDS-PAGE method. The basic steps are as follows: The samples were electrophoretically separated using the Invitrogen electrophoresis tank and SDS-PAGE gradient gel. The sample was diluted to about 1mg / mL, and an appropriate amount of reducing agent, loading buffer and pure water were added. After mixing evenly, it was heated at 70°C for about 10 minutes, the sample load was 2-10μg, the electrophoresis voltage was about 200V, the electrophoresis time was about 35 minutes, and then the gel was stained and destained respectively. After decolorization, a conventional gel imaging system was used to take pictures and analyze and calculate the purity of the main band. Then, the purity of different antibodies was evaluated by size exclusion high performance liquid chromatography (SEC-HPLC). The basic steps are as follows: dilute the sample to about 1.0 mg / mL, use TSKgelG3000SWXL column, set the column temperature to 25°C, use 100 mM phosphate buffer, 100 mM sodium sulfate, pH 7.0±0.2 as the mobile phase, the injection volume is 20-50 μL, at a flow rate of 1.0 mL / min, isocratic elution for 20 min, detection at a wavelength of 280 nm, and the peak area normalization method is used to obtain the monomer content.
[0134] The expression and purity information of two different single-domain antibodies of the present invention are shown in Table 3. The expression levels of the single-domain antibodies of the present invention are 890 and 826 mg / L, respectively. This shows that the single-domain antibodies of the present invention have a higher expression level. The purity of the reduced SDS-PAGE and SEC-HPLC of most single-domain antibodies of the present invention is above 95%. The above results show that the two single-domain structures of the present invention have a good expression level and a higher purity.
[0135] Table 3. Expression level and purity test results of single domain antibodies
[0136]
[0137] Example 3: Detection of the binding ability of single domain antibodies to targets
[0138] This example uses ELISA and flow cytometry to detect the binding ability of candidate single domain antibodies to target antigens at both the protein and cell levels. The specific operation steps are as follows:
[0139] 3.1 Protein level binding capacity detection
[0140] 1) Dilute streptavidin SA protein to 0.3 μg / mL with PBS, add 100 μL / well to a 96-well transparent ELISA plate, seal the plate with a sealing film and incubate at 37°C for 1 hour;
[0141] 2) Discard the protein and wash the plate three times with 200 μL PBST solution (PBS containing 0.05% Tween20);
[0142] 3) Add blocking solution (PBS solution containing 2% BSA) at 100 μL / well, seal the plate with sealing film and incubate at 37°C for 1 hour;
[0143] 4) Repeat the plate washing step 2);
[0144] 5) The biotin-labeled pMHC protein complex loaded with HBV envelope polypeptide was diluted to 2ug / ml with blocking solution, 100μL of diluent was added to each well, the plate was sealed with sealing film and incubated at 37°C for 1h;
[0145] 6) Repeat the plate washing step 2);
[0146] 7) Dilute the candidate single domain antibody to 12 different concentrations with blocking solution, with the highest concentration being 0.3 μg / mL, and dilute 3-fold in a gradient, add 100 μL of diluent to each well, seal the plate with sealing film, and incubate at 37°C for 1 hour;
[0147] 8) Repeat the plate washing step 2);
[0148] 9) Dilute SA-HRP with blocking solution at a ratio of 1:1000, add 100 μL to each well, seal the plate with sealing film and incubate at 37°C for 30 min;
[0149] 10) Repeat the plate washing step 2);
[0150] 11) Add 100 μL of TMB reaction solution to each well, seal the plate with a sealing film and place it on a microplate oscillator for 10 minutes, then add 100 μL of 2N H2SO4 solution to terminate the reaction, and read the absorbance at 450 nm with an enzyme reader.
[0151] The results are as follows Figure 1 As shown. The EC50 values of LL-PR001 and LL-PR002 single domain antibodies binding to antigen protein are 0.00252 and 0.00226 μg / mL respectively. The results show that the two single domain antibodies screened by the present invention can bind to protein antigens and have high affinity.
[0152] 3.2 Cell-level binding ability detection
[0153] 1) Take an appropriate amount of T2 cells (cell bank of Shanghai Institute of Biochemistry and Cell Biology) and adjust the cell density to 2×106 / ml, dispensed into 96-well U-bottom plates, 50 μL per well (about 1E5 cells);
[0154] 2) Peptide loading: Prepare a 60 μM peptide with 1640 medium, add 50 μL / well of the peptide dilution to the well plate and mix with the cells, incubate at 37°C for 2 hours to load the peptide onto the T2 cells. Add 200 μL of 1640 medium to resuspend the cells, centrifuge at 400 g for 5 minutes, and remove the supernatant;
[0155] 3) Antibody incubation: Use antibody diluent (PBS + 0.5% FBS) to adjust the initial concentration of the original antibody to 1 μg / mL, dilute 4 times, and set 10 concentration gradients in total. Take 100 μL of the diluted antibody and add it to the previously loaded cells. After pipetting and mixing, incubate at 4°C in the dark for 60 min.
[0156] 4) Antibody washing: Add 200 μL of antibody diluent to the incubated antibody-cell mixture, centrifuge at 400 g for 5 min, discard the supernatant, resuspend the cells with 200 μL of antibody diluent, and repeat the washing once;
[0157] 5) Secondary antibody incubation: dilute the fluorescent secondary antibody APC anti-human IgG Fc (BD Biosciences) at 1:200 with antibody diluent, take 100 μL and add it to the cell pellet after discarding the supernatant, pipette to mix, and incubate at 4°C in the dark for 30 min;
[0158] 6) Secondary antibody washing: Add 200 μL of antibody diluent to the incubated antibody-cell mixture, centrifuge at 400 g for 5 min, discard the supernatant, resuspend the cells with 200 μL of antibody diluent, and repeat the washing once;
[0159] 7) Detection on the flow cytometer: Add 100 μL of antibody diluent to each tube to resuspend the cells, transfer the cell suspension to the flow cytometer, and detect the positive labeling rate by flow cytometry.
[0160] 8) Analyze the data using FlowJo software to obtain the mean fluorescence intensity (MFI) value, fit the dose-effect nonlinear curve based on the MFI value and antibody concentration value, and calculate the EC 50 Value, to evaluate the antigen affinity activity of candidate antibody molecules.
[0161] The results are as follows Figure 2 As shown. The EC50 values of LL-PR001 and LL-PR002 single domain antibodies binding to antigen protein at the cellular level are 0.0128 and 0.0161 μg / mL respectively. The results show that the two single domain antibodies screened by the present invention can bind to antigens at the cellular level and have high affinity.
[0162] Example 4: Using T2 cell model to detect the specificity of single domain antibody for target recognition
[0163] 1) Take T2 cells grown to the logarithmic phase and resuspend them in complete medium to 2×10 6 / mL;
[0164] 2) Use culture medium to dilute the target peptide and LL-OTP peptide to 60 μM, mix the peptide dilution with the cell suspension at a volume ratio of 1:1, and incubate at 37°C incubator for 1-2 hours to load the peptide onto the T2 cell surface;
[0165] 3) After incubation, the excess peptides were washed away with culture medium, the cells were collected by centrifugation, and the cells were resuspended to 2×10 6 / mL, the peptide-loaded T2 cells were inoculated into a 96-well U-bottom cell culture plate at 50 μL / well;
[0166] 4) Dilute the candidate antibody molecules with buffer to 10 μg / mL, 2 μg / mL, 0.4 μg / mL, and 0.08 μg / mL, respectively, add the antibody dilution to the well plate at 50 μL / well, mix thoroughly with the cells, and incubate at 4°C for 1 hour;
[0167] 5) Centrifuge at 300 g for 5 min, remove the antibody diluent, and wash the cells once with 200 μL buffer;
[0168] 6) Dilute the fluorescent secondary antibody APC anti-human IgG Fc (purchased from Biolegend, catalog number 366906) with buffer at a ratio of 1:200, add the antibody dilution to the well plate at 100 μL / well, resuspend the cells and mix well, and incubate at 4°C for 30 min;
[0169] 7) Centrifuge at 300 g for 5 min, remove the antibody diluent, and wash the cells once with 200 μL buffer;
[0170] 8) Resuspend the cells with 100 μL buffer and detect the fluorescence binding intensity of the APC channel by flow cytometry;
[0171] 9) Analyze the data using FlowJo software to obtain the mean fluorescence intensity (MFI) and evaluate the nonspecific binding level of the candidate antibody molecules to the off-target peptides.
[0172] Table 3. Potential off-target polypeptide sequence list used in the present invention
[0173] Serial number Peptide name Peptide sequence 1 HBVen GLSPTVWLSV (SEQ ID NO: 17) 2 LL-OTP1 AQPTVWLTI (SEQ ID NO: 18) 3 LL-OTP2 SLSPTVWFL (SEQ ID NO: 19) 4 LL-OTP3 LVSGLSPTV (SEQ ID NO: 20) 5 LL-OTP4 GLSPTVAVL (SEQ ID NO: 21)
[0174] The present invention detected the off-target effects of two single domain antibodies. Figure 3The MFI values after data statistics were calculated, and the off-target analysis results of two single-domain antibodies were displayed. Figure 3 As shown, the single domain antibody molecules screened by the present invention have good specificity and can be further developed.
[0175] The above results indicate that the single-domain antibodies screened in the present invention can recognize the HBV envelope polypeptide presented by HLA-A02 with high affinity and specificity, and have the potential to be developed into bispecific antibodies (T cell engagers, etc.) and drugs such as ADC and RDC in the future for HBV infection or HBV-related cancers, which are of great value.
[0176] Example 5: Molecular design of CAR sequence targeting the full-length envelope protein of HBV and construction of lentiviral vector
[0177] 5.1 Design of CAR gene sequence targeting the full-length HBV envelope protein
[0178] The CAR targeting the full-length envelope protein of HBV comprises a single-domain antibody sequence against the full-length envelope protein of human HBV, a CD8 hinge region and a transmembrane domain, a 4-1BB co-stimulatory signal transduction region, and a CD3zeta signal transduction domain, which are connected in series. The present invention selects two single-domain antibody sequences and designs two CAR structures. The two different CAR molecules are named: HBV-CAR-01 and HBV-CAR-02, and the amino acid sequences corresponding to different CARs are shown in Table 4. The two CAR gene sequences targeting the full-length envelope protein of HBV designed by the present invention are synthesized and subcloned into the pUC57 vector (Suzhou Jinweizhi Biotechnology Co., Ltd.).
[0179] Table 4. Amino acid sequence of CAR targeting the full-length HBV envelope protein
[0180]
[0181] 5.2 Construction of CAR Lentiviral Vector
[0182] Primers were designed to use PCR to amplify two different CAR molecules from the pUC57 vector. When designing primers, the homology arms of the lentiviral vector need to be added to the 5' ends of the forward and reverse primers. The amplified PCR products were detected by agarose gel electrophoresis and then gel-recovered and purified (Nanjing Novozyme Biotechnology Co., Ltd., Catalog No. DC301) to obtain DNA fragments. The DNA fragments recovered by enzyme digestion were cloned into the lentiviral vector by homologous recombination. The lentiviral vector needed to be digested and purified by restriction endonucleases BamHI (NEB: R3136V) and SalI (NEB: R3138V). Two different recombinant plasmids were obtained in this way: p-lenti-HBV-CAR-01 and p-lenti-HBV-CAR-02. The two lentiviral vectors were sent to Suzhou GeneWeizhi Biotechnology Co., Ltd. for sequencing verification. The sequencing primers were: Lenti-seqF: TTGAGTTGGATCTTGGTTC (SEQ ID NO: 37), Lenti-seqR: CAGCAACCAGGATTTATACA (SEQ ID NO: 38). Sanger sequencing verified that both lentiviral vector plasmids were constructed correctly.
[0183] Example 6: Preparation and functional evaluation of CAR-T cells targeting the full-length HBV envelope protein
[0184] 6.1 Preparation of Lentivirus
[0185] The correct lentiviral plasmids verified by sequencing were transformed into Escherichia coli stbl3 (purchased from Yisheng Biotechnology Co., Ltd.). The next day, single clones were picked from the transformed plates and placed in a 2ml liquid LB culture tube containing kanamycin (50ug / ml) at 37°C, 220rpm, and shaken for 8h. 1ml was taken from the activated bacterial solution and inoculated into 250ml liquid LB culture medium containing kanamycin, and shaken for 12-16h at 37°C, 220rpm. The plasmid was extracted using the large extraction kit NucleoBond Xtra Midi Plus (MN, catalog number: 740412.50) according to the experimental procedure provided by the kit. After the plasmid was extracted, the plasmid concentration was determined using Nanodrop (Thermo Fisher Scientific) and verified by sanger sequencing, and the supercoiled plasmid content was detected by DNA agarose gel.
[0186] After the frozen 293T cells (purchased from the cell bank of the Chinese Academy of Sciences) were taken out of liquid nitrogen, they were melted in a 37°C water bath, and the tube mouth was wiped with 75% alcohol. They were moved to a 15ml centrifuge tube with 10ml preheated DMEM complete medium (90% DMEM + 10% FBS + 1% penicillin / streptomycin) added, and gently blown evenly. After centrifugation at 400g for 4min, the supernatant was discarded. Then 10ml DMEM complete medium was added, and it was gently blown evenly and inoculated into a T25 or T75 culture flask, and cultured in a cell culture incubator at 37°C containing 5% CO2. The next day, when the cell density reached more than 80%, the cells were subcultured and continued to be cultured. 293T cells cultured for more than 3 generations can be used to package lentivirus. The specific steps are:
[0187] 1) On the first day, 293T cells were inoculated at a rate of approximately 1.0×10 7 Cells were inoculated into each T175 flask (40 mL culture medium) and transfected when the cell density reached 90% on the second day.
[0188] 2) The next day, plasmid transfection: Before transfection, the culture medium was replaced with DMEM medium with 10% FBS but without dual antibodies. Prepare the plasmid complex first: add the following plasmids to 1.5 ml Opti-MEM (Thermo Fisher Scientific; 31985-070) and mix well: 18 μg of psPAX2 plasmid (Addgene; Catalog No.: 12260), 9 μg of pMD2.G plasmid (Addgene; Catalog No.: 12259), 18 μg of lentiviral vector plasmid. The lentiviral plasmids are: p-lenti-HBV-CAR-01, p-lenti-HBV-CAR-02. Then prepare the transfection reagent complex: according to the mass ratio of plasmid to PEI of 1:3, add 67.5μL (2mg / mL) of PEI (polysciences: 24765) to 1.5mL Opti-MEM, mix well, and let stand at room temperature for 5min; then add the transfection reagent complex dropwise to the plasmid complex, mix well and let stand for 20min. Finally, slowly drip the transfection complex into the 293T cell culture flask, mix gently, and continue to culture in a cell culture incubator at 37℃ with 5% CO2.
[0189] 3) On the fourth day, collect the virus: collect the culture medium supernatant 48 hours after transfection, and centrifuge at 2000rpm for 10 minutes to remove cell debris. Use a 0.45μM filter membrane (Millex-HV, catalog number SLHVR33RB) to filter the supernatant, and transfer the filtrate to a special centrifuge tube for balancing. Use an ultracentrifuge for ultracentrifugation at 25000rpm for 2 hours. After pouring out the supernatant, use 1ml of X-VIVO-15 culture medium to resuspend the lentivirus, and store the lentivirus in aliquots at -80℃ ultra-low temperature refrigerator. According to this process, prepare lentivirus containing HBV-CAR-01 and HBV-CAR-02 respectively.
[0190] 6.2 Preparation of CAR-T cells and detection of CAR molecule expression
[0191] The prepared lentivirus containing HBV-CAR-01 and HBV-CAR-02 were used to infect primary human T cells, respectively, to prepare CAR-T cells carrying different CAR genes. The CAR-T cells carrying the two CAR genes were named HBV-CAR-T-01 and HBV-CAR-T-02, respectively, and the untransfected T cells were used as negative controls and named NTD. The specific steps are as follows:
[0192] 1) CD3+ T cells from healthy human peripheral blood were resuscitated (Miaoshun (Shanghai) Biotechnology Co., Ltd.) and resuspended in T cell culture medium containing 300 IU / mL IL-2 to a density of 1×10 6 / mL, add T cell activator CD3 / CD28 magnetic beads (ACRO Biosystems, catalog number: MBS-C001) at a ratio of 1:1 between cells and magnetic beads, mix thoroughly, and then inoculate the cells in a 6-well plate for culture;
[0193] 2) After T cell activation for 24 hours, T cells were counted and inoculated into a new 24-well plate, with 500ul per well and 5×10 5 Cells were inoculated into cells / well. After inoculation, 100 μL of lentivirus solution carrying different CAR genes was added to infect T cells. T cells without virus solution were used as negative control NTD. The cells were placed in an incubator for further culture.
[0194] 3) After 48 hours of infection with lentivirus, the cells were aspirated from the culture wells, the magnetic beads were removed by magnetic adsorption using a magnetic stand, and the cells were collected by centrifugation and resuspended in fresh T cell culture medium.
[0195] 4) Take 100 μL of cell suspension with lentivirus and negative control at the same time, collect cells by centrifugation, resuspend cells with 100 μL FACS buffer, add APC-labeled pMHC protein complex tetramer to each tube of cells, mix well, and incubate at 4°C in the dark for 30 minutes;
[0196] 5) Wash the cells twice with PBS, resuspend the cells in 100 μL FACS buffer, and detect the expression efficiency of the two CARs on T cells by flow cytometry.
[0197] The results showed that both CAR molecules of the present invention could be successfully expressed on T cells, and the expression efficiency was relatively consistent, ranging from 30% to 65% ( Figure 4 ).
[0198] 6.3 Detection of CAR-T cell killing ability
[0199] This experiment uses two HBV target expression positive cell lines as target cells, namely liver cancer HepG2.2.15 and PLC / PRF5. HepG2 cells are used as negative cells, and the two CAR-T cells prepared in Example 6 above are co-cultured with target cells to detect the killing effect and evaluate the biological functions of different CAR-T. The specific steps are as follows:
[0200] 1) Use lentiviral solution expressing GFP luciferase (GenBank: AAR29591.1) to transfect different target cells to obtain cell lines labeled with luciferase, labeled as: HepG2.2.15-GFP-luc, PLC / PRF5 and HepG2-GFP-luc;
[0201] 2) HepG2.2.15-GFP-luc, PLC / PRF5 and HepG2-GFP-luc cells were cultured at a cell concentration of 1×10 5 / mL, 50 μL / well was inoculated into a 96-well flat-bottom opaque cell culture plate and temporarily placed at 37°C for incubation;
[0202] 3) Use NTD to adjust the positive ratio of the two CAR-T cells to 30%, set 3 effector-target ratios of 15:1, 5:1 and 1:1, inoculate the two different CAR-T and control T cell NTDs into the target cells at 50 μL / well for co-culture, mix thoroughly, and incubate in a 37°C incubator overnight;
[0203] 4) Take out the opaque 96-well flat-bottom plate after co-culture, add 100 μL of an equal volume of D-luciferin substrate (Thermo Fisher Scientific: 88293) to the wells, mix well and react in the dark for 10 minutes, and detect the fluorescence intensity in the chemiluminescence mode of the microplate reader. Since luciferase is only expressed in target cells, the remaining luciferase activity in the well is directly related to the number of live target cells. The culture medium is added to the target cells to obtain the maximum luciferase activity as a control, and the target cell apoptosis ratio is calculated by deducting the live cell fluorescence signal value, which is the killing effect of CAR-T cells on target cells. The results are shown in Figure 5 shown.
[0204] The results showed that both CAR molecules described in the present invention can mediate T cell killing of cells positive for the two targets, but have no killing effect on negative cells, among which PLC / PRF5 cells have the strongest killing effect.
[0205] 6.4 Detection of CAR-T cell factor secretion
[0206] In order to further evaluate the level of target cell-specific activation of the CAR-T cells of the present invention and the release of cytokines, the two CAR-T cells prepared in Example 6 were co-cultured with target cells at a 1:1 effector-target ratio for 24 hours, and the levels of IFN-γ and IL-2 cytokines secreted by T cells in the culture supernatant were detected. The specific steps are as follows:
[0207] 1) Take the target cells HepG2.2.15, PLC / PRF5 and HepG2 and resuspend them in complete culture medium to 1×10 6 / mL, the cell suspension was inoculated into a 96-well U-bottom deep-well plate at 100 μL / well;
[0208] 2) After counting the NTD of the two CAR-T cells and the control T cells, the effector-target ratio was 1:1, i.e., the cell concentration was 1×10 6 / mL, 100μL / well was added to different target cells for co-culture.
[0209] 3) After the above cells were co-cultured overnight, 50 μL of the culture supernatant was collected and transferred to a new U-bottom 96-well plate. The secretion of IFN-γ and IL-2 cytokines in T cells was detected using an ELISA kit (Thermo Fisher Scientific; Cat. No. 88-7316). Plate preparation and supernatant cytokine detection were performed according to the instructions provided by the kit;
[0210] 4) Graphpad Prism software was used for data analysis, dose-dependent curve fitting, and EC calculation 50 value.
[0211] The results are as follows Figure 6 As shown. The results show that the candidate CAR-T cells can effectively recognize target cells, activate and transmit immune signals, and secrete IFN-γ and IL-2 cytokines, among which the HBV-CAR-T-02 molecule has relatively better biological activity. Based on the above results, the CAR sequence described in the present invention has good affinity activity and biological function, indicating that the CAR molecule of the present invention has the value of further development and application.
[0212] Example 7: Single domain antibody humanization
[0213] The present invention humanizes the single domain antibody candidate molecule LL-PR002. Basic steps:
[0214] 1) The sequence of the single-domain antibody candidate molecule LL-PR002 was input into the IMGT database for antibody sequence alignment. Based on the database sequence alignment results, IGHV3-23*04 was selected as the LL-PR002 humanized parent vector.
[0215] 2) The CDR region of the LL-PR002 single domain antibody was transplanted into IGHV3-23*04.
[0216] 3) Refer to the prior art literature to perform back mutation on the transplanted humanized antibody to ensure the affinity of the humanized antibody.
[0217] By the above method, 12 candidate humanized single domain antibodies were designed with LL-PR002 as the humanized parent, and the antibody sequences are shown in Table 5.
[0218] Table 5. Humanized single domain antibody sequences designed based on LL-PR002 humanized parent
[0219]
[0220]
[0221] Example 8: Expression of humanized single domain antibody molecules
[0222] The amino acid sequence of the humanized single-domain antibody molecule is first codon-optimized to obtain a nucleotide sequence, and the full-length gene of the humanized antibody molecule is constructed into a single-domain antibody expression vector by gene synthesis. After the vector is successfully constructed, the single-domain antibody is expressed by transient transfection of HEK293 suspension cell lines, and the specific steps are referred to Example 2.
[0223] The expression levels and purities of different humanized single domain antibodies are shown in Table 6. After the humanized single domain antibody of the present invention is expressed using a transient expression system, the expression level of the molecule is in the range of 650-850 mg / L, proving that the humanized single domain antibody of the present invention has a higher expression level. And the purity of the reduced SDS-PAGE and SEC-HPLC of most humanized single domain antibodies is above 95%. These results prove that the humanized single domain antibody of the present invention has a good expression level and a high purity.
[0224] Table 6. Expression and purity detection of humanized single domain antibodies
[0225]
[0226] Example 9: Detection of the binding ability of humanized single domain antibody molecules to targets
[0227] In this example, the binding ability of humanized single domain antibody molecules to target antigens was detected by ELISA, thereby determining the affinity of humanized molecules. For specific experimental operation steps, please refer to Example 3.1. The results show that the candidate humanized single domain antibodies obtained after humanization of LL-PR002 molecules can bind to protein antigens and have high affinity (results are shown in Figure 3). Figure 7 It can be applied to the subsequent research and development of bispecific antibodies, CAR-T, ADC, RDC and other biopharmaceutical projects.
[0228] All documents mentioned in the present invention are cited as references in this application, just as each document is cited as reference individually. In addition, it should be understood that after reading the above teachings of the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms also fall within the scope defined by the claims attached to this application.
Claims
1. A single-domain antibody targeting the full-length envelope protein of HBV, the single-domain antibody comprising CDR1 shown in SEQ ID NO: 2, CDR2 shown in SEQ ID NO: 3, and CDR3 shown in SEQ ID NO: 4; or, the single-domain antibody comprising CDR1 shown in SEQ ID NO: 6, CDR2 shown in SEQ ID NO: 7, and CDR3 shown in SEQ ID NO:
8.
2. A humanized single-domain antibody targeting the full-length HBV envelope protein, wherein the framework regions FR1, FR2, FR3 and FR4 are humanized based on the single-domain antibody described in claim 1.
3. An antibody targeting the full-length envelope protein of HBV, the antibody comprising one or more single-domain antibodies targeting the full-length envelope protein of HBV as described in claim 1 or humanized single-domain antibodies targeting the full-length envelope protein of HBV as described in claim 2.
4. A bispecific antibody, comprising a first antibody and a second antibody, wherein the first antibody comprises the single-domain antibody targeting the full-length envelope protein of HBV according to claim 1, the humanized single-domain antibody targeting the full-length envelope protein of HBV according to claim 2, or the antibody targeting the full-length envelope protein of HBV according to claim 3.
5. A fusion protein, comprising the single-domain antibody targeting the full-length envelope protein of HBV according to claim 1, the humanized single-domain antibody targeting the full-length envelope protein of HBV according to claim 2, or the antibody targeting the full-length envelope protein of HBV according to claim 3, and a linker sequence and an Fc fragment of an immunoglobulin.
6. A nucleic acid molecule, which encodes the single-domain antibody targeting the full-length envelope protein of HBV as described in claim 1, the humanized single-domain antibody targeting the full-length envelope protein of HBV as described in claim 2, the antibody targeting the full-length envelope protein of HBV as described in claim 3, the bispecific antibody as described in claim 4, or the fusion protein as described in claim 5.
7. An expression vector comprising the nucleic acid molecule of claim 6.
8. A host cell, comprising the expression vector of claim 7, or the nucleic acid molecule of claim 6 integrated into its genome.
9. A method for preparing the single domain antibody targeting the full-length HBV envelope protein of claim 1, the humanized single domain antibody targeting the full-length HBV envelope protein of claim 2, the antibody targeting the full-length HBV envelope protein of claim 3, the bispecific antibody of claim 4, or the fusion protein of claim 5, the method comprising the following steps: 1) culturing the host cell according to claim 8 under suitable conditions to obtain a culture containing a single domain antibody targeting the full-length HBV envelope protein, a humanized single domain antibody targeting the full-length HBV envelope protein, an antibody targeting the full-length HBV envelope protein, a bispecific antibody or a fusion protein; as well as 2) isolating or recovering the single domain antibody targeting the full-length HBV envelope protein, the humanized single domain antibody targeting the full-length HBV envelope protein, the antibody targeting the full-length HBV envelope protein, the bispecific antibody or the fusion protein from the culture.
10. An immunoconjugate, comprising: 1) the single domain antibody targeting the full-length envelope protein of HBV according to claim 1, the humanized single domain antibody targeting the full-length envelope protein of HBV according to claim 2, the antibody targeting the full-length envelope protein of HBV according to claim 3, the bispecific antibody according to claim 4 or the fusion protein according to claim 5; and 2) A conjugated moiety selected from the group consisting of a detectable label, a drug, a toxin, a cytokine, or an enzyme.
11. The immunoconjugate according to claim 10, characterized in that The coupling moiety is a radionuclide.
12. A chimeric antigen receptor, comprising the single domain antibody according to claim 1 or prepared by the single domain antibody according to claim 1.
13. An immune effector cell, which expresses the chimeric antigen receptor according to claim 12 on its surface.
14. A pharmaceutical composition comprising a therapeutically or diagnostically effective amount of the single-domain antibody targeting the full-length envelope protein of HBV according to claim 1, the humanized single-domain antibody targeting the full-length envelope protein of HBV according to claim 2, the antibody targeting the full-length envelope protein of HBV according to claim 3, the bispecific antibody according to claim 4, the fusion protein according to claim 5, the immunoconjugate according to claim 10 or the immune effector cell according to claim 13, and a pharmaceutically acceptable excipient.
15. Use of the single-domain antibody targeting the full-length envelope protein of HBV according to claim 1, the humanized single-domain antibody targeting the full-length envelope protein of HBV according to claim 2, the antibody targeting the full-length envelope protein of HBV according to claim 3, the bispecific antibody according to claim 4, the fusion protein according to claim 5, the immunoconjugate according to claim 10, the immune effector cell according to claim 13 or the pharmaceutical composition according to claim 14 in the preparation of a reagent for detecting the full-length envelope protein of HBV, or in the preparation of a drug for treating liver cancer or hepatitis B virus infection.
16. A kit, comprising: 1) The single domain antibody targeting the full-length envelope protein of HBV according to claim 1, the humanized single domain antibody targeting the full-length envelope protein of HBV according to claim 2, the antibody targeting the full-length envelope protein of HBV according to claim 3, the bispecific antibody according to claim 4, the fusion protein according to claim 5, the immunoconjugate according to claim 10, the immune effector cell according to claim 13 or the pharmaceutical composition according to claim 14; 2) container; and 3) Instructions for use.
17. A method for detecting the full-length HBV envelope protein in a sample, the method comprising the steps of: 1) contacting the sample to be tested with the single domain antibody targeting the full-length HBV envelope protein of claim 1, the humanized single domain antibody targeting the full-length HBV envelope protein of claim 2, the antibody targeting the full-length HBV envelope protein of claim 3, the bispecific antibody of claim 4, the fusion protein of claim 5 or the immunoconjugate of claim 10; 2) Detect whether an antigen-antibody complex is formed. If a complex is formed, it indicates that the full-length HBV envelope protein is present in the sample; The method is for non-diagnostic purposes.
Citation Information
Patent Citations
A therapeutic vaccine for hepatitis b virus (HBV) using the HBV pres1 and / or pres2, and / or s-hbsag regions of the HBV envelope protein
CN111542340A
Hepatitis B virus surface S protein high-affinity nano antibody and application thereof
CN114702573A
